Treatment strategies for hepatitis C: making the best of limited options.
Data from two recent major trials suggest that several changes in clinical practice would benefit hepatitis C patients, including viral genotyping to more accurately determine the duration of therapy, and timely RNA measurement to predict treatment response. Although the combination of interferon alfa-2b and ribavirin therapy has proved superior to interferon alone, the success of interferon-based therapies in eradicating hepatitis C is limited, and the quest for new strategies and treatments continues.